ARS Pharmaceuticals, Inc. SPRY Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.68M+184% | $28.09M-67.6% | $32.5M+1,472% | $15.72M+3,043% | $7.97M— | ||
| $4.34M+46.9% | $3.44M+13.7% | $2.75M-37.8% | $4.04M-41.5% | $2.95M-43.6% | ||
| $72.2M+75.7% | $59.96M+68.9% | $74.75M+288% | $54.31M+507% | $41.1M+417% | ||
| $82.83M+83.4% | $69.55M+76.6% | $85.69M+260% | $63.33M+300% | $45.15M+242% | ||
| $82.83M+83.4% | $69.55M+76.6% | $85.69M+260% | $63.33M+300% | $45.15M+242% | ||
| -$60.15M-61.8% | -$41.47M— | -$53.19M-145% | -$47.61M-210% | -$37.18M-182% | ||
| -265.2%+201pp | -147.6%— | -163.7%+888pp | -302.9%+2,765pp | -466.3%— | ||
| -$473K-115% | $61K-98.0% | $2.04M-22.1% | $2.73M-3.3% | $3.24M+11.6% | ||
| —— | -$42.84M-2,168% | -$42.84M-2,168% | -$42.84M-2,168% | -$42.84M-2,168% | ||
| —— | -$20K-128% | -$20K-128% | -$20K-128% | -$20K-128% | ||
| -$60.62M-78.6% | -$41.32M-183% | -$51.15M-167% | -$44.88M-259% | -$33.94M-230% | ||
| -267.3%+158pp | -147.1%-205pp | -157.4%+768pp | -285.6%+2,218pp | -425.7%— | ||
| -$0.61-74.3% | -$0.42-182% | -$0.52-160% | -$0.46-254% | -$0.35-218% | ||
| -$0.61-74.3% | -$0.42-182% | -$0.52-160% | -$0.46-254% | -$0.35-218% | ||
| 99.3M+1.3% | 98.6M-3.7% | 98.8M+1.8% | 98.4M+1.6% | 98.1M+1.6% | ||
| 99.3M+1.3% | 98.6M+1.7% | 98.8M+1.8% | 98.4M+1.6% | 98.1M+1.6% | ||
| $6.29M+475% | $6.15M+611% | $8.19M+7,213% | $4.98M— | $1.09M— | ||
| -$60.84M-78.5% | -$41.19M-183% | -$51.11M-174% | -$45M-259% | -$34.09M-226% | ||
| -$221K-49.3% | —— | $39K-91.9% | -$118K-462% | -$148K+14.5% | ||
| $2.44M— | —— | —— | —— | $0— | ||
| $1.97M-39.2% | —— | —— | —— | $3.24M+13.9% | ||
| -$473K-115% | $61K-98.0% | $2.04M-22.1% | $2.73M-3.3% | $3.24M+11.6% | ||
| $22.68M+184% | $28.09M-67.6% | $32.5M+1,472% | $15.72M+3,043% | $7.97M— | ||
| -$60.15M-61.8% | -$41.47M-2,102% | -$53.19M-145% | -$47.61M-210% | -$37.18M-182% | ||
| -$59.75M-61.9% | -$41.05M-2,054% | -$52.8M-143% | -$47.34M-209% | -$36.9M-180% | ||
| -$59.75M-61.9% | -$41.05M-2,054% | -$52.8M-143% | -$47.34M-209% | -$36.9M-180% | ||
| -263.4%+199pp | -146.1%-149pp | -162.5%+888pp | -301.2%+2,763pp | -462.8%— | ||
| -$60.15M-61.8% | -$41.47M-2,102% | -$53.19M-145% | -$47.61M-210% | -$37.18M-182% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s revenue?
- ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.
- Is ARS Pharmaceuticals, Inc. profitable?
- ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.
- What is ARS Pharmaceuticals, Inc.'s earnings per share?
- ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.
- Where does ARS Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
